BRIEF-Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718)

Reuters

20 Nov 2024

BRIEF-<a href="https://laohu8.com/S/SAGE">Sage Therapeutics</a> Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718)

Nov 20 (Reuters) - SAGE Therapeutics Inc SAGE.O:

SAGE THERAPEUTICS ANNOUNCES TOPLINE RESULTS FROM THE PHASE 2 DIMENSION STUDY OF DALZANEMDOR (SAGE-718) IN THE TREATMENT OF COGNITIVE IMPAIRMENT ASSOCIATED WITH HUNTINGTON’S DISEASE
SAGE THERAPEUTICS INC - DALZANEMDOR DID NOT MEET PRIMARY ENDPOINT IN PHASE 2 STUDY
SAGE THERAPEUTICS INC - DALZANEMDOR GENERALLY WELL-TOLERATED WITH NO NEW SAFETY SIGNALS
SAGE THERAPEUTICS INC - TO HALT FURTHER DEVELOPMENT OF DALZANEMDOR
SAGE THERAPEUTICS - TO CLOSE ONGOING PURVIEW STUDY, AN OPEN-LABEL SAFETY STUDY OF DALZANEMDOR IN PARTICIPANTS WITH HD

Source text: ID:nBw3XvSsba

Further company coverage: SAGE.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2484191539"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2484191539\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2484191539?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-20 19:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2484191539","market":"us","top_or_hot":-1,"title":"BRIEF-Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718)","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/SAGE\">Sage Therapeutics</a> Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718)</title></head><body><p><span>Nov 20 (Reuters)</span><span> - </span>SAGE <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <span>SAGE.O</span>:</p><ul><li><p>SAGE THERAPEUTICS ANNOUNCES TOPLINE RESULTS FROM THE PHASE 2 DIMENSION STUDY OF DALZANEMDOR (SAGE-718) IN THE TREATMENT OF COGNITIVE IMPAIRMENT ASSOCIATED WITH HUNTINGTON’S DISEASE</p></li><li><p>SAGE THERAPEUTICS INC - DALZANEMDOR DID NOT MEET PRIMARY ENDPOINT IN PHASE 2 STUDY</p></li><li><p>SAGE THERAPEUTICS INC - DALZANEMDOR GENERALLY WELL-TOLERATED WITH NO NEW SAFETY SIGNALS</p></li><li><p>SAGE THERAPEUTICS INC - TO HALT FURTHER DEVELOPMENT OF DALZANEMDOR</p></li><li><p>SAGE THERAPEUTICS - TO CLOSE ONGOING PURVIEW STUDY, AN OPEN-LABEL SAFETY STUDY OF DALZANEMDOR IN PARTICIPANTS WITH HD</p></li></ul><p>Source text: <span>ID:nBw3XvSsba</span></p><p>Further company coverage: <span>SAGE.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718)\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2024-11-20 19:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/SAGE\">Sage Therapeutics</a> Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718)</title></head><body><p><span>Nov 20 (Reuters)</span><span> - </span>SAGE <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <span>SAGE.O</span>:</p><ul><li><p>SAGE THERAPEUTICS ANNOUNCES TOPLINE RESULTS FROM THE PHASE 2 DIMENSION STUDY OF DALZANEMDOR (SAGE-718) IN THE TREATMENT OF COGNITIVE IMPAIRMENT ASSOCIATED WITH HUNTINGTON’S DISEASE</p></li><li><p>SAGE THERAPEUTICS INC - DALZANEMDOR DID NOT MEET PRIMARY ENDPOINT IN PHASE 2 STUDY</p></li><li><p>SAGE THERAPEUTICS INC - DALZANEMDOR GENERALLY WELL-TOLERATED WITH NO NEW SAFETY SIGNALS</p></li><li><p>SAGE THERAPEUTICS INC - TO HALT FURTHER DEVELOPMENT OF DALZANEMDOR</p></li><li><p>SAGE THERAPEUTICS - TO CLOSE ONGOING PURVIEW STUDY, AN OPEN-LABEL SAFETY STUDY OF DALZANEMDOR IN PARTICIPANTS WITH HD</p></li></ul><p>Source text: <span>ID:nBw3XvSsba</span></p><p>Further company coverage: <span>SAGE.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241120:nTUABTQTNG:1","article_id":"2484191539","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2484191539","pubTimestamp":1732102321,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718)Nov 20 (Reuters) - SAGE Therapeutics Inc SAGE.O:SAGE THERAPEUTICS ANNOUNCES TOPLINE RESULTS ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"简介–Sage Therapeutics公布Dalzanemdor(SAGE-718)2期DIMENSION研究的主要结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SAGE":0.9},"content_text":"BRIEF-Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718)Nov 20 (Reuters) - SAGE Therapeutics Inc SAGE.O:SAGE THERAPEUTICS ANNOUNCES TOPLINE RESULTS FROM THE PHASE 2 DIMENSION STUDY OF DALZANEMDOR (SAGE-718) IN THE TREATMENT OF COGNITIVE IMPAIRMENT ASSOCIATED WITH HUNTINGTON’S DISEASESAGE THERAPEUTICS INC - DALZANEMDOR DID NOT MEET PRIMARY ENDPOINT IN PHASE 2 STUDYSAGE THERAPEUTICS INC - DALZANEMDOR GENERALLY WELL-TOLERATED WITH NO NEW SAFETY SIGNALSSAGE THERAPEUTICS INC - TO HALT FURTHER DEVELOPMENT OF DALZANEMDORSAGE THERAPEUTICS - TO CLOSE ONGOING PURVIEW STUDY, AN OPEN-LABEL SAFETY STUDY OF DALZANEMDOR IN PARTICIPANTS WITH HDSource text: ID:nBw3XvSsbaFurther company coverage: SAGE.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}